PRISM BioLab and Receptor.AI Partner for AI Drug Discovery
TOKYO, Japan & CAMBRIDGE, Mass., March 13, 2026 PRISM BioLab Co., Ltd. and Receptor.AI Inc. have announced a strategic...
cGxPwire Editor
Equillium Secures $35M Financing to Advance EQ504
LA JOLLA, Calif., March 13, 2026 Equillium Inc., a biotechnology company developing novel therapies for severe autoimmune and inflammatory...
NORD and OpenEvidence Partner for Rare Disease AI
NORWELL, Mass., and MIAMI, Fla., March 12, 2026 The National Organization for Rare Disorders (NORD) and OpenEvidence have announced...
Emerald Clinical Trials Wins ABEA Patient Recruitment Award
SINGAPORE, March 12, 2026 Emerald Clinical Trials, a leading global clinical research organization (CRO), has been honored with the...
George Medicines Signs Korea Deal to Commercialize GMRx2
LONDON, UK, March 11, 2026 George Medicines, a late-stage biopharmaceutical company focused on cardiometabolic diseases, has announced an exclusive...
NEXGEL to Acquire Regenerative Biomaterial Product Portfolio
LANGHORNE, Pa., March 12, 2026 NEXGEL, Inc. has announced the consideration terms of an agreement to license and acquire...
PROCEPT Launches HYDROS AI Robotic System for BPH Care
SAN JOSE, Calif., March 12, 2026 PROCEPT BioRobotics has announced the international launch of its HYDROS® Robotic System, a...
Vima Therapeutics Doses First Patient in Phase 2 Trial
CAMBRIDGE, Mass., March 11, 2026 Vima Therapeutics has announced a major milestone in its drug development pipeline, confirming that...
CSL Invests $1.5B to Expand Illinois Plasma Therapy Facility
KING OF PRUSSIA, Pa., March 9, 2026 CSL Limited, a global biopharmaceutical leader, has announced a $1.5 billion investment...
FDA Launches AEMS Adverse Event Safety Platform
SILVER SPRING, Md., March 11, 2026 The U.S. Food and Drug Administration (FDA) has launched a new unified safety...